Stephanie Sommer, PhD, is affiliated with Global Regulatory Affairs at Boehringer Ingelheim International GmbH in Ingelheim am Rhein, Germany. Her publications focus on clinical trials investigating the efficacy, tolerability, and safety of the TRPC4/5 inhibitor BI 1358894 in patients with major depressive disorder and borderline personality disorder. Her work primarily addresses treatment responses in these psychiatric conditions.
1 Read counts for articles published before 2020 may include some non-human traffic.
2 Citation counts provided by Crossref.
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.
